ICAM-1 promotes cancer progression by regulating SRC activity as an adapter protein in colorectal cancer

Colorectal cancer (CRC) has a 5-year survival rate of <10%, as it can metastasize to the lungs and liver. Anticancer drugs and targeted therapies used to treat metastatic colorectal cancer have insufficient therapeutic efficacy and are associated with complications. Therefore, research to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Eun-Ji, Kang, Jae-Hyeok, Kim, Yeon-Ju, Kim, Seungmo, Lee, Su-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054780/
https://www.ncbi.nlm.nih.gov/pubmed/35487888
http://dx.doi.org/10.1038/s41419-022-04862-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054780/
https://www.ncbi.nlm.nih.gov/pubmed/35487888
http://dx.doi.org/10.1038/s41419-022-04862-1

Ejemplares similares